Literature DB >> 16121690

VX-950 (Vertex/Mitsubishi).

Vincenzo Summa1.   

Abstract

Vertex and Mitsubishi are developing VX-950 (LY-570310), the lead compound from a program of small-molecule inhibitors of the hepatitis C virus (HCV) NS3 protease, for the potential treatment of HCV infection. In November 2004, Vertex initiated a phase Ib European trial of VX-950 for the treatment of HCV infection.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16121690

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  3 in total

1.  Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative.

Authors:  Wataru Ito; Masaaki Toyama; Mika Okamoto; Masanori Ikeda; Koichi Watashi; Takaji Wakita; Yuichi Hashimoto; Masanori Baba
Journal:  Antivir Chem Chemother       Date:  2016-08-19

2.  Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.

Authors:  Leen Delang; Inge Vliegen; Mathy Froeyen; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

3.  Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.

Authors:  Lotte Coelmont; Suzanne Kaptein; Jan Paeshuyse; Inge Vliegen; Jean-Maurice Dumont; Grégoire Vuagniaux; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.